Anavex Life Scie Stock Price, News & Analysis

Anavex Life Sciences (NASDAQ:AVXL) reported its fiscal 2025 Q3 financial results and provided updates on its clinical developments. The company's lead drug candidate blarcamesine demonstrated continued clinical benefits for early-stage Alzheimer's patients over a 4-year period, as presented at AAIC 2025.

Financial highlights include cash position of $101.2 million as of June 30, 2025, providing over 3 years of runway. Q3 net loss was $13.2 million ($0.16 per share), compared to $12.2 million ($0.14 per share) in Q3 2024. R&D expenses decreased to $10.0 million from $11.8 million year-over-year, while G&A expenses increased to $4.5 million from $2.8 million.

Anavex Life Sciences (NASDAQ:AVXL), a clinical-stage biopharmaceutical company, will release its fiscal 2025 third quarter financial results on Tuesday, August 12, 2025. The company will host a conference call at 8:30 am ET the same day.

Anavex focuses on developing innovative treatments for various conditions including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other CNS disorders. Management will discuss financial results and provide updates on the company's growth strategy, followed by a Q&A session.

Anavex Life Sciences (NASDAQ:AVXL) announced positive results from up to 4 years of oral blarcamesine treatment in a Phase IIb/III open-label extension trial for early Alzheimer's disease. The study demonstrated significant benefits with up to 84.6 weeks (19.5 months) of 'time saved' in disease progression for early-start treatment patients.

Key findings in the GWAS-identified ABCLEAR24 population (71.7% global frequency) showed substantial improvements in cognition (ADAS-Cog13, -5.43, P=0.0035) and function (ADCS-ADL, +9.50, P<0.0001). The drug demonstrated a favorable safety profile with no treatment-related deaths. The study confirmed blarcamesine's mechanism of restoring impaired autophagy as an early event, preceding amyloid-beta and tau pathologies.

Anavex Life Sciences (NASDAQ: AVXL), a clinical-stage biopharmaceutical company developing treatments for neurological conditions, announced its participation in two upcoming healthcare conferences. CEO Christopher U. Missling will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th, 2025, at 2:30 pm ET, and the H.C. Wainwright 6th Annual Neuro Perspectives Conference on June 17th, 2025, at 7:00 pm ET. Both events will be held in New York City, with webcasts available to firm clients at hcwevents.com.

The company focuses on innovative treatments for various conditions including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other CNS disorders.

Anavex Life Sciences reported its Q2 FY2025 financial results and business updates. The company ended Q2 with $115.8 million in cash, projecting a 4-year runway. Financial results showed a net loss of $11.2 million ($0.13 per share), compared to $10.5 million in Q2 FY2024. Key developments include completing enrollment in the Phase 2 ANAVEX®3-71 schizophrenia trial with 71 participants, with top-line data expected in H2 2025. The company also presented promising long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension trial, showing continued clinical benefits for early Alzheimer's disease patients over three years of blarcamesine treatment. Additionally, Anavex strengthened its Scientific Advisory Board with the appointment of Dr. Audrey Gabelle, a neurology expert from Montpellier University.

Anavex Life Sciences (Nasdaq: AVXL), a clinical-stage biopharmaceutical company, will release its fiscal 2025 second quarter financial results on Tuesday, May 13, 2025. The company will host a conference call and webcast at 8:30 am ET the same day, where management will discuss financial results and provide updates on the company's growth strategy.

Anavex focuses on developing innovative treatments for various CNS disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other neurodegenerative and rare diseases. The conference call will be accessible via webcast on www.anavex.com or by phone for U.S. participants at 1-929-205-6099 using Meeting ID# 856 5033 5285 and passcode 014 352. A replay will be available on the company's website for up to 30 days.

Anavex Life Sciences (NASDAQ: AVXL) has completed enrollment in its Phase 2 clinical study of ANAVEX®3-71 for schizophrenia treatment. The study (ANAVEX3-71-SZ-001) enrolled 71 total participants across two parts: Part A (16 participants) studying multiple ascending doses, and Part B (55 participants) for longer treatment duration. Part A has been completed with encouraging preliminary safety and EEG biomarker results.

ANAVEX®3-71 is an oral dual SIGMAR1 receptor agonist and M1 positive allosteric modulator, designed to potentially treat all schizophrenia symptom domains without standard antipsychotic side effects. The company expects to report top-line data in the second half of 2025.

Anavex Life Sciences (Nasdaq: AVXL), a clinical-stage biopharmaceutical company, has announced its participation in The Citizens Life Sciences Conference in New York. The event will take place from May 7-8, 2025.

The company's President & CEO, Christopher U Missling, PhD, is scheduled to deliver a presentation on Wednesday, May 7th, 2025, at 3:30 PM ET. Anavex specializes in developing innovative treatments for:

• Alzheimer's disease
• Parkinson's disease
• Schizophrenia
• Neurodevelopmental disorders
• Neurodegenerative conditions
• Rett syndrome
• Other CNS disorders

Anavex Life Sciences (Nasdaq: AVXL) has appointed Professor Dr. Audrey Gabelle, MD, PhD to its Scientific Advisory Board. Dr. Gabelle, a specialist in predictive, personalized medicine and digital health in Alzheimer's disease, brings extensive expertise as a Professor of Neurology at Montpellier University.

Dr. Gabelle's credentials include managing 400+ memory centers within the French network, authoring 200+ peer-reviewed scientific papers, and 10+ years of experience in clinical Phase I-IV trials. She has expertise in diagnosis and biomarkers through the NeuroCognition biobank, which contains over 35,000 samples. Her recent focus includes real-world evidence, digital health strategies, and AI, with training from Columbia and Harvard Universities.

The appointment aims to support the development of blarcamesine (ANAVEX®2-73), an oral treatment for Alzheimer's disease that has shown clinically meaningful improvement and good safety profile.